Fiche société
NS Pharma, Inc.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| NS-050/NCNP-03This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping. | Myopathies | Phase 1/2 | À vérifier | United States, Canada, Japan, South Korea, Turkey (Türkiye) | À vérifier |
| NS-050/NCNP-03This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping. | Myopathies | Phase 1/2 | À vérifier | United States, Canada, Japan, South Korea, Turkey (Türkiye) | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| NS-050/NCNP-03 | Myopathies | Phase 1/2 | NCT06053814 | NS-050/NCNP-03 in Boys With DMD (Meteor50) | ACTIVE_NOT_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||